Gvalani Aanchal, Athavale Amita, Gupta Disha
Medical Affairs, GlaxoSmithKline, Mumbai, Maharashtra, India.
Department of Pulmonary Medicine and EPRC, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India.
Lung India. 2023 Jan-Feb;40(1):59-67. doi: 10.4103/lungindia.lungindia_271_22.
Asthma is a chronic condition of bronchial hyper-reactivity associated with inflammation ranges from mild to severe form. It affects 1 - 18% of the population globally and it is estimated that > 300million people in the world have asthma. Of this 5 - 10% have severe asthma. while the proportion of patients suffering from severe are smaller, the morbidity and mortality are higher in this group. With the advances in our understanding of the pathophysiology of asthma there is a need to understand the role of various biomarkers. We live in an era of precision medicine and today there is a clear unmet need to understand targeted therapies. This review aims to raise awareness to the available biomarkers used in clinical practice in India and their role in predicting response to targeted therapies.
哮喘是一种与炎症相关的支气管高反应性慢性病，炎症程度从轻度到重度不等。全球1%-18%的人口受其影响，据估计，全球有超过3亿人患有哮喘。其中5%-10%为重度哮喘。虽然重度哮喘患者比例较小，但该群体的发病率和死亡率较高。随着我们对哮喘病理生理学认识的进步，有必要了解各种生物标志物的作用。我们生活在精准医学时代，如今明确存在对了解靶向治疗的未满足需求。本综述旨在提高对印度临床实践中使用的现有生物标志物及其在预测靶向治疗反应中的作用的认识。
